Biogen (BIIB)
(Delayed Data from NSDQ)
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $211.68, marking a +0.34% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $206.81, marking a -0.84% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
by Zacks Equity Research
Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $209.45, marking a -0.84% move from the previous day.
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down
by Zacks Equity Research
Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
by Zacks Equity Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
by Zacks Equity Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
by Zacks Equity Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day.
Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.